Arcus Biosciences Inc. (RCUS)
| Bid | 10.64 |
| Market Cap | 987.41M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -3.19 |
| PE Ratio (ttm) | -3.38 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 11 |
| Volume | 936,914 |
| Avg. Volume (20D) | 782,245 |
| Open | 10.98 |
| Previous Close | 11.10 |
| Day's Range | 10.63 - 11.05 |
| 52-Week Range | 10.63 - 20.31 |
| Beta | undefined |
About RCUS
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Pha...
Analyst Forecast
According to 9 analyst ratings, the average rating for RCUS stock is "Buy." The 12-month stock price forecast is $29, which is an increase of 168.77% from the latest price.
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
Arcus Biosciences: Many Important Oncology Catalysts Coming Up In 2025Arcus Biosciences has interesting combination therapies that target several diseases like NSCLC, RCC, GI, and pancreatic cancers. The company has a few ongoing Phase 3 trials, some of which will repor...
